HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Symrise sales

This article was originally published in The Rose Sheet

Executive Summary

Scent and Care division revenues increased 6.5% on a local-currency basis to $1.03 bil. in 2007, the fragrance and flavor company announces March 5. The performance of the business was boosted by 10.6% growth in cosmetics and 8.5% local currency growth rate in fine fragrances based on "winning some major prestigious new fragrances in 2007," firm says. Symrise achieved net sales growth of 6.7% to $1.96 bil. in fiscal 2007 based on its concentration on fast-growing regions and business segments, German firm notes. Symrise is poised to maintain 5%-6% sales growth per year in 2008 and 2009, the company maintains...

You may also be interested in...



Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.

UsernamePublicRestriction

Register

RS015295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel